Good manufacturing practices production of a purification-free oral cholera vaccine expressed in transgenic rice plants

Koji Kashima, Yoshikazu Yuki, Mio Mejima, Shiho Kurokawa, Yuji Suzuki, Satomi Minakawa, Natsumi Takeyama, Yoshiko Fukuyama, Tatsuhiko Azegami, Takeshi Tanimoto, Masaharu Kuroda, Minoru Tamura, Yasuyuki Gomi, Hiroshi Kiyono

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Key message: The first Good Manufacturing Practices production of a purification-free rice-based oral cholera vaccine (MucoRice-CTB) from transgenic plants in a closed cultivation system yielded a product meeting regulatory requirements. Abstract: Despite our knowledge of their advantages, plant-based vaccines remain unavailable for human use in both developing and industrialized countries. A leading, practical obstacle to their widespread use is producing plant-based vaccines that meet governmental regulatory requirements. Here, we report the first production according to current Good Manufacturing Practices of a rice-based vaccine, the cholera vaccine MucoRice-CTB, at an academic institution. To this end, we established specifications and methods for the master seed bank (MSB) of MucoRice-CTB, which was previously generated as a selection-marker-free line, evaluated its propagation, and given that the stored seeds must be renewed periodically. The production of MucoRice-CTB incorporated a closed hydroponic system for cultivating the transgenic plants, to minimize variations in expression and quality during vaccine manufacture. This type of molecular farming factory can be operated year-round, generating three harvests annually, and is cost- and production-effective. Rice was polished to a ratio of 95 % and then powdered to produce the MucoRice-CTB drug substance, and the identity, potency, and safety of the MucoRice-CTB product met pre-established release requirements. The formulation of MucoRice-CTB made by fine-powdering of drug substance and packaged in an aluminum pouch is being evaluated in a physician-initiated phase I study.

Original languageEnglish
Pages (from-to)667-679
Number of pages13
JournalPlant Cell Reports
Volume35
Issue number3
DOIs
Publication statusPublished - 2016 Mar 1
Externally publishedYes

Fingerprint

good manufacturing practices
cholera
mouth
genetically modified organisms
vaccines
rice
transgenic plants
molecular farming
educational institutions
drugs
pouches
buried seeds
factories
physicians
hydroponics
developed countries
aluminum
developing countries
manufacturing
seeds

Keywords

  • GMP production
  • Molecular farming
  • MucoRice
  • Oral vaccine
  • Seed bank

ASJC Scopus subject areas

  • Agronomy and Crop Science
  • Plant Science

Cite this

Good manufacturing practices production of a purification-free oral cholera vaccine expressed in transgenic rice plants. / Kashima, Koji; Yuki, Yoshikazu; Mejima, Mio; Kurokawa, Shiho; Suzuki, Yuji; Minakawa, Satomi; Takeyama, Natsumi; Fukuyama, Yoshiko; Azegami, Tatsuhiko; Tanimoto, Takeshi; Kuroda, Masaharu; Tamura, Minoru; Gomi, Yasuyuki; Kiyono, Hiroshi.

In: Plant Cell Reports, Vol. 35, No. 3, 01.03.2016, p. 667-679.

Research output: Contribution to journalArticle

Kashima, K, Yuki, Y, Mejima, M, Kurokawa, S, Suzuki, Y, Minakawa, S, Takeyama, N, Fukuyama, Y, Azegami, T, Tanimoto, T, Kuroda, M, Tamura, M, Gomi, Y & Kiyono, H 2016, 'Good manufacturing practices production of a purification-free oral cholera vaccine expressed in transgenic rice plants', Plant Cell Reports, vol. 35, no. 3, pp. 667-679. https://doi.org/10.1007/s00299-015-1911-9
Kashima, Koji ; Yuki, Yoshikazu ; Mejima, Mio ; Kurokawa, Shiho ; Suzuki, Yuji ; Minakawa, Satomi ; Takeyama, Natsumi ; Fukuyama, Yoshiko ; Azegami, Tatsuhiko ; Tanimoto, Takeshi ; Kuroda, Masaharu ; Tamura, Minoru ; Gomi, Yasuyuki ; Kiyono, Hiroshi. / Good manufacturing practices production of a purification-free oral cholera vaccine expressed in transgenic rice plants. In: Plant Cell Reports. 2016 ; Vol. 35, No. 3. pp. 667-679.
@article{bd68edc87ad243808c5e5dafb3e3f36d,
title = "Good manufacturing practices production of a purification-free oral cholera vaccine expressed in transgenic rice plants",
abstract = "Key message: The first Good Manufacturing Practices production of a purification-free rice-based oral cholera vaccine (MucoRice-CTB) from transgenic plants in a closed cultivation system yielded a product meeting regulatory requirements. Abstract: Despite our knowledge of their advantages, plant-based vaccines remain unavailable for human use in both developing and industrialized countries. A leading, practical obstacle to their widespread use is producing plant-based vaccines that meet governmental regulatory requirements. Here, we report the first production according to current Good Manufacturing Practices of a rice-based vaccine, the cholera vaccine MucoRice-CTB, at an academic institution. To this end, we established specifications and methods for the master seed bank (MSB) of MucoRice-CTB, which was previously generated as a selection-marker-free line, evaluated its propagation, and given that the stored seeds must be renewed periodically. The production of MucoRice-CTB incorporated a closed hydroponic system for cultivating the transgenic plants, to minimize variations in expression and quality during vaccine manufacture. This type of molecular farming factory can be operated year-round, generating three harvests annually, and is cost- and production-effective. Rice was polished to a ratio of 95 {\%} and then powdered to produce the MucoRice-CTB drug substance, and the identity, potency, and safety of the MucoRice-CTB product met pre-established release requirements. The formulation of MucoRice-CTB made by fine-powdering of drug substance and packaged in an aluminum pouch is being evaluated in a physician-initiated phase I study.",
keywords = "GMP production, Molecular farming, MucoRice, Oral vaccine, Seed bank",
author = "Koji Kashima and Yoshikazu Yuki and Mio Mejima and Shiho Kurokawa and Yuji Suzuki and Satomi Minakawa and Natsumi Takeyama and Yoshiko Fukuyama and Tatsuhiko Azegami and Takeshi Tanimoto and Masaharu Kuroda and Minoru Tamura and Yasuyuki Gomi and Hiroshi Kiyono",
year = "2016",
month = "3",
day = "1",
doi = "10.1007/s00299-015-1911-9",
language = "English",
volume = "35",
pages = "667--679",
journal = "Plant Cell Reports",
issn = "0721-7714",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Good manufacturing practices production of a purification-free oral cholera vaccine expressed in transgenic rice plants

AU - Kashima, Koji

AU - Yuki, Yoshikazu

AU - Mejima, Mio

AU - Kurokawa, Shiho

AU - Suzuki, Yuji

AU - Minakawa, Satomi

AU - Takeyama, Natsumi

AU - Fukuyama, Yoshiko

AU - Azegami, Tatsuhiko

AU - Tanimoto, Takeshi

AU - Kuroda, Masaharu

AU - Tamura, Minoru

AU - Gomi, Yasuyuki

AU - Kiyono, Hiroshi

PY - 2016/3/1

Y1 - 2016/3/1

N2 - Key message: The first Good Manufacturing Practices production of a purification-free rice-based oral cholera vaccine (MucoRice-CTB) from transgenic plants in a closed cultivation system yielded a product meeting regulatory requirements. Abstract: Despite our knowledge of their advantages, plant-based vaccines remain unavailable for human use in both developing and industrialized countries. A leading, practical obstacle to their widespread use is producing plant-based vaccines that meet governmental regulatory requirements. Here, we report the first production according to current Good Manufacturing Practices of a rice-based vaccine, the cholera vaccine MucoRice-CTB, at an academic institution. To this end, we established specifications and methods for the master seed bank (MSB) of MucoRice-CTB, which was previously generated as a selection-marker-free line, evaluated its propagation, and given that the stored seeds must be renewed periodically. The production of MucoRice-CTB incorporated a closed hydroponic system for cultivating the transgenic plants, to minimize variations in expression and quality during vaccine manufacture. This type of molecular farming factory can be operated year-round, generating three harvests annually, and is cost- and production-effective. Rice was polished to a ratio of 95 % and then powdered to produce the MucoRice-CTB drug substance, and the identity, potency, and safety of the MucoRice-CTB product met pre-established release requirements. The formulation of MucoRice-CTB made by fine-powdering of drug substance and packaged in an aluminum pouch is being evaluated in a physician-initiated phase I study.

AB - Key message: The first Good Manufacturing Practices production of a purification-free rice-based oral cholera vaccine (MucoRice-CTB) from transgenic plants in a closed cultivation system yielded a product meeting regulatory requirements. Abstract: Despite our knowledge of their advantages, plant-based vaccines remain unavailable for human use in both developing and industrialized countries. A leading, practical obstacle to their widespread use is producing plant-based vaccines that meet governmental regulatory requirements. Here, we report the first production according to current Good Manufacturing Practices of a rice-based vaccine, the cholera vaccine MucoRice-CTB, at an academic institution. To this end, we established specifications and methods for the master seed bank (MSB) of MucoRice-CTB, which was previously generated as a selection-marker-free line, evaluated its propagation, and given that the stored seeds must be renewed periodically. The production of MucoRice-CTB incorporated a closed hydroponic system for cultivating the transgenic plants, to minimize variations in expression and quality during vaccine manufacture. This type of molecular farming factory can be operated year-round, generating three harvests annually, and is cost- and production-effective. Rice was polished to a ratio of 95 % and then powdered to produce the MucoRice-CTB drug substance, and the identity, potency, and safety of the MucoRice-CTB product met pre-established release requirements. The formulation of MucoRice-CTB made by fine-powdering of drug substance and packaged in an aluminum pouch is being evaluated in a physician-initiated phase I study.

KW - GMP production

KW - Molecular farming

KW - MucoRice

KW - Oral vaccine

KW - Seed bank

UR - http://www.scopus.com/inward/record.url?scp=84958841861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958841861&partnerID=8YFLogxK

U2 - 10.1007/s00299-015-1911-9

DO - 10.1007/s00299-015-1911-9

M3 - Article

C2 - 26661780

AN - SCOPUS:84958841861

VL - 35

SP - 667

EP - 679

JO - Plant Cell Reports

JF - Plant Cell Reports

SN - 0721-7714

IS - 3

ER -